N/A N=6 Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling
Fibrosing Alopecia · Frontal Fibrosing Alopecia · Central Centrifugal Cicatricial Alopecia
Primary: Total Area Hair Count (Frontal) — 86.8 Count per cm^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=35 A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
Frontal Fibrosing Alopecia
Primary: Change in Expression of Chemokine (C-X-C Motif) Ligand 9 (CXCL9), Chemokine (C-X-C Motif) Ligand 10 (CXCL10), and Interferon (IFN)-γ From Baseline to Week 12. — -3.10…
Phase 2 N=51 Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia
Cicatricial Alopecia
Primary: Number of Participants With Treatment-Emergent Adverse Events — 0; 3 Participants
Phase 4 N=20 Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)
Central Centrifugal Cicatricial Alopecia
Primary: Mean Change in Physician Global Assessment of Improvement (PGA-I) — 0.07 score on a scale
N/A N=11 Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study
Frontal Fibrosing Alopecia · Lichen Planopilaris of Scalp
Primary: Effectiveness of Oral Tofacitinib in Recalcitrant Frontal Fibrosing Alopecia(FFA) — 47.5; 44; 16.3; 15.9 score on a scale
Phase 2 N=43 Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia
Lichen Planopilaris · Frontal Fibrosing Alopecia
Primary: Change in Patient-Reported Itch — -0.33 units on a scale
N/A N=30,901 Healthcare Disparities in Alopecia Areata
Alopecia Areata
Primary: Likelihood of Depressive Episodes — 1217; 3576 Participants
N/A N=7 Adipose-derived SVF for Treatment of Alopecia
Androgenetic Alopecia
Primary: Incidence of Treatment-emergent Adverse Events (Safety) — 0 adverse events
Phase 2 N=60 Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
Alopecia Areata
Primary: Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -6.3; 2.3 score on a scale
Phase 3 N=718 PF-06651600 for the Treatment of Alopecia Areata
Alopecia Areata
Primary: Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24 — 30.65; 22.31; 23.39; 14.29 Percentage of…
Phase 3 N=15 Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)
Alopecia
Primary: Hair Density Change After Three Treatments — 175.1 percentage of pre-treatment hair density
N/A N=45 Alefacept in Patients With Severe Scalp Alopecia Areata
Alopecia Areata
Primary: The Proportion of Subjects Achieving at Least a 50% Reduction in Their Scalp Alopecia Areata Severity Scores (SALT Score) From Baseline Values — 8.7; 13.6 percentage of…
N/A N=71 STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia
Alopecia, Androgenetic
Primary: Safety & Tolerability Assessment of SAE/AE — 5; 9; 12; 2 events
N/A N=30 Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata
Alopecia Areata
Primary: Number of Patients With SALT50 — 1; 1 Participants
Phase 2 N=87 ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
Alopecia
Primary: Percent Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -25.6; -30.4; -25.9; -6.3 percent — p=0.011
Phase 2 N=15 An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
Alopecia Areata
Primary: Total Number of Participants With At Least 50% Hair Regrowth — 1 Participants
Phase 3 N=322 Clinical Trial in Females With Female Pattern Hair Loss
Alopecia
Primary: Target Area Hair Count (TAHC) — 167.3; 169.7; 192.8; 194.4 hairs per centimeter squared — p=0.9170
N/A N=24 A Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia
Central Centrifugal Cicatricial Alopecia
Primary: Shape of the Hairline Documented With Photographs — 8; 12; 2 Participants
Phase 2 N=14 Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata
Alopecia Areata
Primary: Change in Alopecia Areata Half Head Severity Score (AAHHSS) at 12 Weeks Compared to Baseline — -17.75 score on a scale
N/A N=8 Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling
Androgenic Alopecia
Primary: Total Area Hair Count — 126.8 hairs per cm^2
Phase 3 N=404 Clinical Trial in Females for Female Pattern Hair Loss
Androgenetic Alopecia
Primary: Target Area Hair Count — 152.7; 158.6; 162.2; 175.7 hairs per centimeter squared — p=<0.0001
Phase 3 N=407 European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Alopecia Areata
Primary: Number of Participants With Adverse Events as a Measure of Safety — 308; 224 Participants
Phase 2 N=10 Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
Alopecia Areata · Alopecia Totalis · Alopecia Universalis
Primary: Percent Change in Severity of Alopecia Tool (SALT) Score — 10 percent change
Phase 2 N=30 Tofacitnib for the Treatment of Alopecia Areata and Variants
Alopecia Areata (AA) · Alopecia Totalis (AT) · Alopecia Universalis (AU)
Primary: Mean Change in Severity of Alopecia Tool (SALT) Score — 22.8 percent change in SALT score
N/A N=63 Treatment of Androgenetic Alopecia in Females, 12 Beam
Androgenetic Alopecia · Hair Loss · Female Pattern Baldness
Primary: Change in Hair Count at 16 and 26 Weeks Over Baseline — -0.8; 12.5; 3.0; 20.6 hairs per cm^2
Phase 2 N=120 To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin
Androgenic Alopecia
Primary: Scalp Hair Density — 1.46; 2.58; -4.10; 6.68 Change from baseline (No. of hairs/cm2)
N/A N=30 The Effect of Platelet Rich Plasma on Non-scarring Alopecia
Androgenetic Alopecia · Alopecia
Primary: Number of Participants With Improvement — 8; 1 Participants
N/A N=72 Treatment of Androgenetic Alopecia in Females, 9 Beam
Androgenetic Alopecia · Hair Loss · Female Pattern Baldness
Primary: Changes in Terminal Hair Count Week 16 and 26 Weeks Over Baseline — 1.3; 14.8; 2.8; 20.2 hairs per cm^2
Phase 3 N=606 A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
Alopecia Areata
Primary: Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 — 2.6; 17.3; 32.5 percentage of participants — p=<0.001
N/A N=40 Tofacitinib for the Treatment of Alopecia Areata and Its Variants
Alopecia Areata · Alopecia Totalis · Alopecia Universalis
Primary: Percent Change in Severity of Alopecia Tool (SALT) Score — 30.7 Percent change — p=<0.0001